Most material SEC filings — July 13, 2026

Matinas BioPharma Holdings (clinical-stage biopharmaceutical, $4.5M market cap) agreed to merge with GH Power Inc. (Ontario-based clean energy/critical minerals company) via a dual transaction: GH Power amalgamates with Merger Sub A to form Canada Surviving Corp (subsidiary of Pubco), then Matinas merges with Merger Sub B to become subsidiary of Pubco. Matinas shareholders receive 0.1 Pubco Common Shares per Matinas share; GH Power shareholders receive Pubco shares per Plan of Arrangement. Combined entity to list on NYSE.

Babcock & Wilcox announced redemption of all $61.4 million principal of 6.50% Senior Notes due 2026 at par (100% of principal) on August 13, 2026, plus accrued interest and make-whole amount. Simultaneously, the Board authorized a $50 million share repurchase program beginning after Q2 2026 10-Q filing, executable via open market or negotiated transactions at management discretion with no expiration or purchase obligation. Redemption will eliminate remaining outstanding notes; repurchase program is discretionary and subject to lender approval.

BNB Plus Corp. (BNBX) received a delisting determination from Nasdaq on July 14, 2026, due to non-compliance with the $1.00 minimum bid price requirement. The company will transition to trading on OTCQB Venture Market under the same ticker (BNBX) and has requested Nasdaq Listing Council review, though the request does not stay delisting. The company remains a fully reporting public company with the SEC.

Tonix announced a managed Medicare payer agreement effective January 1, 2027, covering approximately 9 million Medicare beneficiaries (16% of ~55 million U.S. Medicare lives). Combined with two prior commercial payer agreements and Medicaid availability, total pharmacy coverage reaches ~145 million covered lives (46% of 314 million U.S. covered lives). In response, Tonix is expanding its sales force by 50 representatives (to ~150 total) by mid-Q3 2026.

Q32 Bio reported 36-week topline results from Part B of SIGNAL-AA trial of bempikibart (anti-IL-7Rα antibody) in 33 patients with severe/very severe alopecia areata: mean 35.3% reduction in SALT score (primary endpoint), 40% achieved SALT-20 response in mITT analysis, generally well-tolerated with no new safety signals. Company intends to advance into registration-directed program in first half of 2027.

First Hawaiian, Inc. (FHB) agreed to acquire TriCo Bancshares (TCBK) for $63.12/share ($2,022mm aggregate value) in an all-stock transaction at a fixed ratio of 2.095 FHB shares per TCBK share. The combined entity will have ~$34bn in assets, making it the 6th largest bank headquartered in the Western U.S., with pro forma ownership of ~65% FHB shareholders and ~35% TCBK shareholders. The deal is expected to close by end of 2026, subject to regulatory and shareholder approvals.

First Hawaiian, Inc. (market cap ~$3.1B) agreed to acquire TriCo Bancshares for $2.022 billion in aggregate, or $63.12 per share, at a fixed exchange ratio of 2.095 FHB shares per TCBK share. The transaction creates a $34 billion asset combined entity, the 6th largest bank headquartered in the Western U.S., with FHB shareholders owning ~65% and TriCo shareholders ~35% post-close. Deal is expected to close by end of 2026, subject to regulatory and shareholder approvals. FHI projects ~6% 2027E EPS accretion (with full cost synergies), $61M in annual pre-tax run-rate cost savings, 4.7% TBVPS dilution with 2.8-year earnback, and high-teens internal rate of return.

Chief Executive Officer Seto Wai Yue (TDIC) bought 652K shares (~$2.4M) on the open market (89% of holdings). Open-market insider purchase — historically a bullish signal.

Effective January 1, 2027, Compass Diversified (CODI, market cap ~$419M) amended its management services agreement with Compass Group Management LLC, reducing the base management fee from 2.00% to 1.25% of Adjusted Net Assets (tiered down to 1.00% above $5B ANA), with a 2027 cap of $30 million. The prior single incentive fee is replaced with two awards: a Share Alignment Award (0.125% of average ANA) and a Performance-Based Award (0.125% target, 70% TSR/30% EBITDA, with zero payout if negative TSR or share price+distributions below $17.25). Expected 2027 savings: $19–22 million versus prior formula. Agreement amended nine times since 2006.

Chief Executive Officer Huang Jack Jiajia (COE) bought 563K shares (~$9.3M) on the open market (1.8% of holdings). Open-market insider purchase — historically a bullish signal.

Resideo Technologies completed its Investor Day presentation on July 13, 2026, ahead of the planned August 3, 2026 spin-off of ADI Global Distribution. Post-spin, Resideo will be a pure-play building technologies company with FY2025 standalone adjusted revenue of $2.9B and $581M standalone adjusted EBITDA (20.3% margin). The company targets 4-5% revenue CAGR through 2030, gross margin expansion to 43-45%, and adjusted EBITDA margin expansion to 23-25% by 2030, with net leverage target of 2.0x within ~24 months post-spin. Spin shareholders will receive 1 ADIG share per 2 REZI shares held.

Executive Chairman Hannigan Todd (IPX) bought 525K shares (~$1.9M) on the open market (1.9% of holdings). Open-market insider purchase — historically a bullish signal.

One year after acquiring The Shyft Group (July 1, 2025) and listing on NASDAQ, Aebi Schmidt raised its annual synergy target from $25–30M to at least $40M (pre-merger targets vs. current run-rate). FY2025 combined revenue was $1.907B with 8.2% adjusted EBITDA margin; Q1 2026 saw 29% YoY order intake growth and 21% adjusted EBITDA growth. Management targets >$3B revenue and mid-teens EBITDA margin by 2030 via organic growth (~6% CAGR), ~$500M M&A, and $400M from synergies/operational improvements.

Armata received FDA agreement on an Agreed Initial Pediatric Study Plan (iPSP) for AP-SA02, establishing a regulatory framework for pediatric evaluation in complicated Staphylococcus aureus bacteremia patients up to age 17. Pediatric studies will be deferred until adult Phase 3 data are generated (Phase 3 expected to start H2 2026), followed by a single open-label pediatric safety/efficacy study. No financial figures, counterparties beyond FDA, or share counts disclosed.

Plug Power agreed to sell its Graham, Texas project (66.3 acres, 164 MW interconnection) to Stream US Data Centers for $50 million at closing (expected July 31, 2026) plus up to $26.5 million contingent on final MW load in interconnection agreement. Simultaneously, parties restructured the New York Gateway Project sale into staged closings: Stream's $6.5 million prior escrow released to Plug, Stream depositing new $10 million toward land purchase, long-stop date extended to March 31, 2027 for non-land assets. Combined transactions expected to generate ~$80 million near-term liquidity, with additional $14 million from released collateral.

Hillman Solutions launched a debt refinancing comprising a $735M Term Loan B (maturing 2033, arranged by Jefferies) and $375M ABL facility (maturing 2031, arranged by U.S. Bank) to refinance existing 2027-2028 obligations. Q2 2026 preliminary results show net sales of $440–$444M (up 9–10% YoY) and adjusted EBITDA of $76–$78M (up 1–4% YoY); full-year 2026 guidance reiterated at $1.63–$1.73B sales and $275–$285M adjusted EBITDA.

Picard Medical announced Q1 2026 results showing 85% YoY revenue increase (116% in U.S.) and gross margin improvement from -4% in 2025 to 24% in Q1 2026. The company also detailed its Emperor platform development roadmap with FDA Breakthrough Device pursuit, planned IDE submission in 2028, and clinical studies targeting 2029. Leadership transition noted with Richard Fang as Interim CEO.